Physician profile
Raphael Tshibangu
NPI 1518935378
$593.19
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $184 · 2021: $49.76 · 2022: $153.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $124.72 | 2019-2022 | |
| Coopersurgical, INC. | $104.07 | 2019-2022 | |
| Allergan, INC. | $82.59 | 2019-2020 | |
| Exeltis, USA INC. | $54.60 | 2020 | |
| Pfizer INC. | $53.41 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $45.34 | 2019 | |
| Lupin INC. | $29.68 | 2019 | |
| Daiichi Sankyo INC. | $23.25 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.96 | 2020 | |
| Therapeuticsmd, INC. | $20.07 | 2020 | |
| Glaxosmithkline, LLC. | $18.47 | 2021 | |
| Amgen INC. | $16.03 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raphael Tshibangu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.